Sermorelin

What Is Sermorelin?

Sermorelin is a synthetic peptide made up of the first 29 amino acids of GHRH, the natural hormone the hypothalamus uses to signal the pituitary gland to release growth hormone. Research in the early 1980s established that this 29-amino-acid fragment retains the full biological activity of the complete 44-amino-acid hormone, which is why sermorelin was built to this exact length rather than the whole molecule.

Sermorelin has a genuine pharmaceutical history that distinguishes it from most compounds on this site. It was FDA-approved under the brand name Geref starting in 1990, first as a diagnostic tool for growth hormone deficiency and later as a treatment for children with growth failure. The manufacturer discontinued the branded product commercially in 2008, and the FDA has been explicit that this wasn't due to safety or efficacy concerns.

What Sermorelin Is Being Researched For

• Pediatric Growth Hormone Deficiency

  The core clinical evidence for sermorelin comes from its original approved use. A multicenter trial found that daily sermorelin produced sustained increases in growth velocity in growth hormone-deficient children over 12 months of treatment.^[1]

• Diagnostic Use for Growth Hormone Deficiency

  Beyond treatment, sermorelin has also been studied and used as a diagnostic tool, since how a patient's pituitary responds to a sermorelin dose can help distinguish different causes of growth hormone deficiency.^[2]

• Growth Hormone Decline in Adults

  Separate from its pediatric approval, sermorelin-related research has extended into adult populations, including a study examining long-term GHRH(1-29) administration in older men and women and its effects on the growth hormone and metabolic axis.^[3]

How Sermorelin Works

• Signaling the Pituitary to Release Growth Hormone

  Research points to sermorelin binding to the GHRH receptor on pituitary cells, triggering the same signaling pathway the body's own GHRH uses to prompt growth hormone release.^[1]

• Preserving the Body's Natural Release Pattern

  Research points to sermorelin working through the body's existing feedback mechanisms rather than bypassing them, meaning it prompts the pituitary to produce and release its own growth hormone rather than supplying growth hormone directly. This is a meaningfully different approach than direct growth hormone administration.^[2]

• A Short, Pulsatile Signal

  Research points to sermorelin's short half-life being a functional feature rather than a limitation, producing a discrete pulse of growth hormone release that mirrors the body's natural pulsatile secretion pattern rather than a sustained elevation.

Reconstitution and Handling

Sermorelin is typically supplied as a lyophilized powder in a sealed vial and reconstituted with bacteriostatic water before use. Water should be added slowly rather than injected directly into the powder, and the vial should be swirled, not shaken.

Since the amount of water used affects the concentration of the final solution, researchers often use a dosage calculator to work this out before mixing. Once reconstituted, the solution is kept refrigerated to help preserve its stability.

Key Takeaways

Sermorelin stands apart from most research peptides for having a genuine, decade-long FDA approval history backed by real pediatric clinical trial data, even though the branded product isn't currently marketed. Its mechanism, prompting the pituitary's own growth hormone release rather than supplying it directly, is a meaningful distinction from direct hormone therapy. Research has since extended into adult and aging populations, building on that original pediatric foundation.

Frequently Asked Questions

Sources and Research

1. Thorner M, Rochiccioli P, Colle M, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-1196.
2. Prakash A, Goa KL. Sermorelin: A Review of its Use in the Diagnosis and Treatment of Children with Idiopathic Growth Hormone Deficiency. BioDrugs. 1999;12(2):139-157.
3. Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479.